Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Depreciation and Depletion: 2023-2025

Historic Depreciation and Depletion for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $2.1 million.

  • Monte Rosa Therapeutics' Depreciation and Depletion fell 0.38% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 5.31%. This contributed to the annual value of $8.1 million for FY2024, which is 30.52% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Depreciation and Depletion of $2.1 million as of Q3 2025, which was down 1.41% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Depreciation and Depletion registered a high of $2.1 million during Q2 2025, and its lowest value of $1.2 million during Q1 2023.
  • In the last 3 years, Monte Rosa Therapeutics' Depreciation and Depletion had a median value of $2.0 million in 2025 and averaged $1.9 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first surged by 58.33% in 2024, then dropped by 0.38% in 2025.
  • Monte Rosa Therapeutics' Depreciation and Depletion (Quarterly) stood at $1.8 million in 2023, then rose by 11.65% to $2.1 million in 2024, then declined by 0.38% to $2.1 million in 2025.
  • Its Depreciation and Depletion stands at $2.1 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.0 million for Q1 2025.